POS-335 COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS A TREATMENT FOR CHRONIC KIDNEY DISEASE: A HEALTH-ECONOMIC ANALYSIS OF DAPA-CKD
P. MCEWAN,
O. Darlington,
D. Wheeler,
H. Heerspink,
K. Bergenheim,
J. Garcia Sanchez
Affiliations
P. MCEWAN
HEOR, Health Economics and Outcomes Research, Cardiff, United Kingdom
O. Darlington
HEOR, Health Economics and Outcomes Research, Cardiff, United Kingdom
D. Wheeler
George Institute for Global Health-, George Institute, Sydney, Australia; University College London, Department of Renal Medicine, London, United Kingdom
H. Heerspink
Department of Clinical Pharmacy and Pharmacology-, University Medical Center Groningen-, Groningen, Netherlands; George Institute for Global Health, George Institute, Sydney, Australia
K. Bergenheim
AstraZeneca, CVRM Biopharmaceutical, Gothenburg, Sweden
J. Garcia Sanchez
AstraZeneca, AstraZeneca, Cambridge, United Kingdom
